OGSIVEO Merck Healthcare Pty Ltd
Product name
OGSIVEO
Sponsor
Accepted date
Jul-2026
Active ingredients
nirogacestat hydrobromide
Summary of proposed indication
OGSIVEO (nirogacestat, as hydrobromide) is proposed as a treatment in adult patients with progressing desmoid tumours who require whole-body treatment. Desmoid tumours are non-cancerous growths that form in connective tissue. They do not spread to other parts of the body, but they can grow locally and cause tissue and organ damage.
Application type
A (new medicine)
Publication date
Jul-2026
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.